1008517-97-2

Upstream product

• 626-03-9 3-deazauracil 
• 100-39-0 benzyl bromide 
• 1008517-95-0 2-bromo-1-[4-(hydroxymethyl)phenyl]ethanone 
• 53937-02-3 4-(benzyloxy)pyridin-2(1H)-one 
• 1008517-96-1 4-benzyloxy-1-[2-(4-hydroxymethyl-phenyl)-2-oxo-ethyl]-1H-pyridin-2-one 

Downstream Products

• 1184945-53-6 4-benzyloxy-1-{2-[4-(4-methoxy-4-methyl-piperidin-1-ylmethyl)-phenyl]-2-oxo-ethyl}-1H-pyridin-2-one 
• 1184949-08-3 4-benzyloxy-1-[2-(4-imidazol-1-ylmethyl-phenyl)-2-oxo-ethyl]-1H-pyridin-2-one 

Relevant academic research and scientific papers

Design, synthesis and evaluation of MCH receptor 1 antagonists - Part III: Discovery of pre-clinical development candidate BI 186908

Abstract Although overweight and obesity are highly prevalent conditions, options to treat them are still very limited. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, two series of pyridones and pyridazinones

PYRIDONE AND PYRIDAZINONE DERIVATIVES AS MCH ANTAGONISTS

The present invention relates to pyridone and pyridazinone derivatives as listed in claim 1 including their salts. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of thei

NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS

The present invention relates to compounds of general formula (I) wherein the groups and radicals B, k, L, U,V, W, X, Y, Z, R1, R2, have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH- receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.